Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

WeightWatchers gains on announced acquisition of Sequence digital health platform

Published 03/08/2023, 02:24 AM
© Reuters.
WW
-

By Michael Elkins

Shares of WW International Inc (NASDAQ:WW) (commonly known as WeightWatchers) surged more than 50% Tuesday following the company’s announcement that the weight loss company has entered into a definitive agreement to acquire subscription telehealth platform, Sequence.

Launched in 2021, Sequence now serves about 24,000 members across the U.S., as of February 2023, and clocks about $25 million in annual revenue on a run-rate basis. Sequence members have highlighted the benefits of its service, including support in navigating the insurance approval process and the quality care they receive from clinicians.

The telehealth platform's website says its clinicians can prescribe medications like Novo Nordisk's (NYSE:NVO) Wegovy and Saxenda, and Eli Lilly's (NYSE:LLY) Mounjaro.

Currently, Wegovy and Saxenda are approved drugs for obesity in the United States, with tirzepatide also widely expected to be approved for it later this year.

Pursuant to the terms of the merger agreement, WW will acquire Sequence in a cash and equity transaction valued at $132M: $100M at the closing of the transaction, of which $65M ($39M, net of Sequence’s cash) will be paid in cash and $35M in the form of 8.065M newly issued shares of common stock of WW; then $16M in cash on the first and second anniversaries of the closing.

“As science advances rapidly, we know there is a significant opportunity to improve outcomes for those using medications. Clinical interventions require better education, access, care management, community and the integration of a complementary lifestyle program for best results. It is our responsibility, as the trusted leader in weight management, to support those interested in exploring if medications are right for them,” said Sima Sistani, CEO of WeightWatchers.

“With our science-backed lifestyle program and Sequence’s tech platform – which puts complex, slow insurance processes on tech rails – this is an unmatched opportunity for us to create an integrated product offering. We want to ensure we have the best programs and experiences for everyone. Together, we will provide impactful, holistic solutions for people living with overweight or obesity,” said Sistani.

The transaction is subject to customary closing conditions, and is expected to close during the second quarter of 2023.

Shares of WW are up 50.65% in afternoon trading on Tuesday.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.